What is the safest approach to discontinue tirzepatide after a patient has lost approximately 60 lb using 5 mg daily for one year?

Do Not Abruptly Stop Tirzepatide After Achieving Weight Loss Goals

After achieving a 60 lb weight loss on tirzepatide 5 mg weekly for one year, continuing the medication is strongly recommended rather than stopping, as discontinuation leads to substantial weight regain that is proportional to the amount originally lost.

The Evidence on Weight Regain After Stopping

The most compelling data comes from the SURMOUNT-MAINTAIN trial 1, which directly addresses this scenario. When patients who achieved weight loss with tirzepatide were switched to placebo, they experienced significant weight regain. The trial demonstrated that:

• Continuing tirzepatide at maximum tolerated dose maintained -21.9% weight loss at 112 weeks
• Switching to placebo resulted in only -9.9% weight loss maintained (meaning substantial regain occurred)
• 67% of placebo patients regained at least 50% of their lost weight and required rescue therapy

A systematic review and meta-analysis 2 confirms this pattern across multiple studies: patients who discontinued semaglutide/tirzepatide regained an average of 9.69 kg (95% CI 5.78 to 13.60), with weight regain proportional to the original weight loss achieved. This weight regain occurred regardless of lifestyle interventions, establishing that these medications should be considered chronic therapy to prevent weight regain and associated adverse outcomes.

The Dose-Reduction Alternative

If continuing at the current dose is not feasible, dose reduction to 5 mg weekly is superior to complete discontinuation. The SURMOUNT-MAINTAIN trial 1 showed that patients who reduced from higher doses (10-15 mg) to 5 mg weekly maintained -16.6% weight loss at 112 weeks, compared to only -9.9% with placebo. Only 25% of patients on 5 mg tirzepatide regained ≥50% of lost weight, versus 67% on placebo.

This provides a critical middle ground: reducing to 5 mg maintains most of the weight loss benefit while potentially reducing cost and side effects.

Real-World Discontinuation Data

Real-world evidence 3 from 7,938 patients who discontinued semaglutide or tirzepatide reveals important patterns:

• Only 19.6% restarted the original medication within one year
• 35.2% received alternative obesity treatment (27.4% started another medication, 13.7% had lifestyle visits, 0.6% underwent bariatric surgery)
• 45% received no further obesity treatment after discontinuation

The mean weight change one year post-discontinuation was relatively small (+0.5% when treating obesity), but this masked considerable individual-level variability—some patients maintained loss while others regained substantially.

Clinical Decision Algorithm

Option 1: Continue Current Dose (Preferred)

• Maintains weight loss most effectively 1
• Monitor for side effects, particularly gastrointestinal symptoms 4
• Counsel that this is chronic therapy for obesity management 2
• Address cost/insurance barriers proactively (the leading cause of discontinuation) 5

Option 2: Reduce to Maintenance Dose

• If cost, side effects, or patient preference necessitate change
• Since patient is already on 5 mg weekly, this dose is appropriate for maintenance 1
• Expect to maintain approximately 75-80% of weight loss achieved
• Monitor weight monthly for first 3 months after any dose change

Option 3: Discontinuation (Least Preferred)

• Only if medically necessary or patient adamantly refuses continuation
• Counsel patient to expect weight regain of 50-70% of lost weight 2
• Intensify lifestyle interventions (though evidence shows limited efficacy alone) 2
• Establish close follow-up (monthly for 6 months) to monitor weight
• Have plan for medication reinitiation if weight regain exceeds 50% of lost weight 1
• Consider alternative obesity pharmacotherapy 3

Critical Counseling Points

Patients must understand that obesity is a chronic disease requiring ongoing treatment 4. The 2025 AACE guidelines 4 emphasize that tirzepatide acts centrally on weight regulation, and discontinuation removes this therapeutic effect. The SURMOUNT-4 trial demonstrated that continuing treatment for 88 weeks resulted in weight reduction up to 26%, while discontinuation led to regain 4.

If the patient must restart after a treatment gap, they will need to restart at 2.5 mg weekly and re-titrate upward to avoid clinically significant gastrointestinal side effects 4. This "start low, go slow" approach is essential after any prolonged interruption.

Common Pitfalls to Avoid

• Assuming lifestyle interventions alone will maintain weight loss: The evidence clearly shows weight regain occurs despite lifestyle modifications 2
• Stopping medication after achieving goal weight: This treats obesity as an acute condition rather than chronic disease
• Not addressing cost barriers proactively: Cost/insurance issues cause 47.6% of discontinuations 5
• Failing to establish a monitoring plan: If discontinuation occurs, close follow-up is essential to detect early regain

The Bottom Line

For a patient who has successfully lost 60 lbs on tirzepatide 5 mg weekly, continuing the medication indefinitely is the evidence-based approach to maintain weight loss and associated cardiometabolic benefits 4, 1. The 5 mg weekly dose is already an appropriate maintenance dose. If continuation is not possible, dose reduction is preferable to complete discontinuation, and complete discontinuation should only occur with full patient understanding of expected weight regain and a robust monitoring and intervention plan.